Study | No. of patients | Age (years) | Male patients N (%) | Duration of AS (years) | Study Duration (weeks) | Medications allowed during the study | Modified Jadad Score | Risk of bias | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sequence generation | Allocation concealment | blinding | Incomplete outcome data | Selective outcome reporting | other sources of bias | ||||||||
ADA | |||||||||||||
van der Heijde D. 2006 [31] | 315 | 24 | DMARDs, NSAIDs and glucocorticoids | 6 | ? | ? | √ | √ | √ | √ | |||
ADA 40 mg every 2 weeks | 208 | 41.7 ± 11.69 | 157 (75.5) | 11.3 ± 9.99 | |||||||||
Placebo | 107 | 43.4 ± 11.32 | 79 (73.8) | 10.0 ± 8.34 | |||||||||
ETA | |||||||||||||
Brandt J. 2003 [32] | 30 | 24 | NSAIDs | 8 | √ | √ | √ | √ | √ | √ | |||
ETA 25 mg twice weekly | 14 | 38.9 ± 9.1 | 10 (71.4) | 14.9 ± 8.3 | |||||||||
Placebo | 16 | 32.0 ± 7.5 | 12 (75) | 11.4 ± 8.8 | |||||||||
Davis JC Jr. 2003 [33] | 277 | 24 | DMARDs, NSAIDs and glucocorticoids | 6 | ? | ? | √ | √ | √ | √ | |||
ETA 25 mg twice weekly | 138 | 42.1 (24–70) | 105 (76) | 10.1 (0–30.7) | |||||||||
Placebo | 139 | 41.9 (18–65) | 105 (76) | 10.5 (0–35.3) | |||||||||
van der Heijde D. 2006 [34] | 356 | 12 | DMARDs, NSAIDs and glucocorticoids | 6 | ? | ? | √ | √ | √ | √ | |||
ETA 25 mg twice weekly | 150 | 39.8 ± 10.7 | 114 (76) | 10.0 ± 9.1 | |||||||||
ETA 50 mg weekly | 155 | 41.5 ± 11.0 | 109 (70) | 9.0 ± 8.7 | |||||||||
Placebo | 51 | 40.1 ± 10.9 | 40 (78) | 8.5 ± 6.8 | |||||||||
IFX | |||||||||||||
Braun J. 2002 [35] | 69 | 12 | NSAIDs | 8 | √ | √ | √ | √ | √ | √ | |||
IFX 5 mg/Kg | 34 | 40.6 ± 8.0 | 23 (68) | 16.4 ± 8.3 | |||||||||
Placebo | 35 | 39.0 ± 9.1 | 22 (63) | 14.9 ± 9.3 | |||||||||
Marzo-Ortega H. 2005 [36] | 42 | 30 | NSAIDs, oral corticosteroids | 8 | √ | √ | √ | √ | √ | √ | |||
IFX 5 mg/Kg + MTX | 28 | 41 (28–74) | 23 (82.14) | 8 (0–41) | |||||||||
Placebo + MTX | 14 | 39 (30–56) | 11 (78.57) | 10 (0–35) | |||||||||
GOL | |||||||||||||
Inman RD. 2008 [37] | 356 | 24 | NSAIDs, MTX, SSA, HCQ, corticosteroids | 7 | ? | ? | √ | √ | √ | √ | |||
GOL 50 mg | 138 | 38 (29–46) | 102 (73.8) | 5.15 (1.60–11.60) | |||||||||
GOL 100 mg | 140 | 38 (30–47) | 98 (70.0) | 5.20 (1.50–13.25) | |||||||||
Placebo | 78 | 41 (31–50) | 55 (70.5) | 7.25 (2.80–18.60) | |||||||||
CZP | |||||||||||||
Landewé R. 2014 [38] | 325 | 24 | DMARDs, NSAIDs, MTX, SSA | 6 | ? | ? | √ | √ | √ | √ | |||
CZP 200 mg every 2 weeks | 111 | 39.1 ± 11.9 | 67 (60.4) | 6.9 (0.3–34.2) | |||||||||
CZP 400 mg every 4 weeks | 107 | 39.8 ± 11.3 | 68 (63.6) | 7.9 (0.3–44.8) | |||||||||
Placebo | 107 | 39.9 ± 12.4 | 65 (60.7) | 7.7 (0.3–50.9) |